A new drug regimen containing the antibody-drug conjugate (ADC) polatuzumab vedotin-piiq is challenging the previous first-line standard for diffuse large B-cell lymphoma (DLBCL), results of the multinational, phase 3 POLARIX trial show.
For nearly 20 years, R-CHOP (rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone) has been the standard first-line therapy for DLBCL. But substituting polatuzumab vedotin (Polivy, Genentech) for vincristine in this regimen